Diagnostic Deals: Urgent Need for Coronavirus Diagnostics Fuels Strategic Collaboration
...
Already a member? Log in here
Diagnostic Deals: Lab Corp & Quest to Continue Targeting Small and Independent Labs for Acquisition
PAMA price cuts were supposed to drive consolidation in the lab market. The expectation was that price pressures would make it impossible for smaller labs to remain independent, rendering them juicy targets for the likes of
Already a member? Log in here
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will apparently continue as stand-alones in the coming year, one because it wants to and the other because it has to.
Already a member? Log in here
Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance
Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close in mid-2019, is now on indefinite hold due to regulatory antitrust
Already a member? Log in here
Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month
Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the key deals that did come down over the 4-week period beginning in late September 2019.
Already a member? Log in here